Targeted Degradation of SOS1 Shows Anticancer Activity in KRAS-Mutant Tumors and BCR–ABL-Positive Leukemia
Author Information
Author(s): Ziwei Luo, Chencen Lin, Chuwei Yu, Changxian Yuan, Wenyong Wu, Xiaowei Xu, Renhong Sun, Yan Jia, Yafang Wang, Jie Shen, Dingyan Wang, Sinan Wang, Hualiang Jiang, Biao Jiang, Xiaobao Yang, Chengying Xie
Primary Institution: ShanghaiTech University
Hypothesis
Can the PROTAC SIAIS562055 effectively degrade SOS1 and enhance treatment outcomes in KRAS-mutant cancers and BCR–ABL-positive leukemia?
Conclusion
SIAIS562055 effectively degrades SOS1, inhibits downstream signaling, and shows strong anticancer activity in both KRAS-mutant tumors and BCR–ABL-positive leukemia.
Supporting Evidence
- SIAIS562055 showed strong antiproliferative activity in KRAS-mutant cancer cells.
- The drug effectively degraded SOS1 and inhibited downstream ERK signaling.
- SIAIS562055 enhanced the efficacy of KRAS inhibitors in resistant cancer models.
- It also improved the uptake of BCR–ABL inhibitors in leukemia cells.
- Combination therapy with SIAIS562055 and imatinib showed synergistic effects in CML.
Takeaway
A new drug called SIAIS562055 can help fight certain types of cancer by breaking down a protein that helps cancer cells grow.
Methodology
The study involved developing a PROTAC to target SOS1, testing its effects on cancer cell lines and mouse models.
Limitations
The study primarily focuses on in vitro and in vivo models, which may not fully represent human responses.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website